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1.1. History of Malaria 
 
Malaria is one of the oldest and most devastating parasitic diseases in humans. 
Hippocrates (460 BC–370 BC) was the first to describe clearly the different types of 
malaria depending upon the periodicity of the fever patterns. The Romans recognized the 
relationship of stagnate water in the swamps surrounding Rome and the presence of fevers 
during the summer months. Initially, these fevers were attributed to bad air —mal aria 
(mal = bad, aria = air) — since they thought that the foul vapors emanating from the 
stagnate water and swamps were the cause of the disease. Though this explanation was 
incorrect, at least it represented an appreciation of the importance of stagnate water 
somehow being related to the summer fall febrile illnesses among the Romans [1]. 300 
years later, the Italian term mal' aria was introduced into England by Horace Walpole in a 
letter he wrote on 5 July 1740 [2]. 
In 1800s, malaria was endemic in all of Central Europe; to this point it was well-known 
that patients who died of malaria had black deposits in their organs. Heinrich Meckel 
conducted an autopsy of a patient with mental illness and found the brain to be dark 
brown, but he did not associate the pigment with malaria. Only a few years later did 
Virchow and Frerichs establish the causal relationship of this brown pigment to malaria, 
and malaria was recognized to be a disease of the blood.  
Charles Alphonse Laveran, the first scientist to see the malarial organism in blood in 
1880, intensely disliked the name malaria. He considered the term unscientific and vulgar, 
preferring the name “paludisme” (Latin: palus = swamp) which is still used in France 
today [3]. 
In 1897, motivated by his mentor Manson, Ronald Ross started to research whether 
mosquitoes could transmit malaria. He detected characteristic pigmented bodies in the 
stomach wall of mosquitoes, now known to be Anopheles species. After several years, 
Ross would prove the complete life cycle of the parasite [4]. 
In 1898, Giovanni Battista Grassi, an Italian zoologist, unequivocally identified Anopheles 
claviger (Greek anofelís = good-for-nothing) as the sole vector of malaria in Italy. 
Between 1885 and 1892, Bartolomeo Camillo Golgi studied the asexual cycle of the 
malaria parasite. He observed that the febrile bouts coincided with segmentation. In 
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addition, Golgi found that the two types of intermittent malarial fevers (tertian, 48 hour 
periodicity, and quartan, 72 hour periodicity) were caused by different species of 
Plasmodium [5]. 
In 1900, Manson provided convincing experimental proof of the mosquito’s role in 
propagating malarial fevers. He imported Anopheles mosquitoes from Rome, which were 
allowed to bite the hand of his son, and after 14 days the son had a severe attack of fever 
[6].  
In 1947, Henry Shortt and Cyril Garnham were finally able to show a primary division of 
the parasite in liver cells [7]. Subsequently, Krotoski and colleagues discovered that some 
P. vivax strains, which are called hipnozoites today, could remain in this liver stage for 
several months [8]. 
Until the 19th century, malaria was spread throughout the north of Europe, North America 
and Russia; in the south of Europe the transmission was intense. However, it has since 
been eradicated from these areas, dropping the number of cases and deaths in these 
regions. However, in the tropics there was an increase in malaria cases because of the 
selection of resistant mosquitoes to insecticides and parasites against the drugs. 
Today, there are more than 200 known species of the genus Plasmodium, but just five of 
these are agents of human malaria: P. vivax, P. ovale, P. malariae, P. knowlesi and the 
most virulent, P. falciparum [9]. The genus Plasmodium belongs to the phylum 
Apicomplexa, which consists of a large group of unicellular eukaryotes sharing the same 
invasion machinery, the apical complex. 
1.1.1. Distribution  
Malaria infections were responsible for an estimated 216 million clinical cases in 2016, 
most were in Africa (90%), next was South-East Asia region (7%) and the Eastern 
Mediterranean region (2%). The population at risk is distributed in tropical and sub-
tropical areas, where of the 91 countries reporting endogenous malaria cases in 2016, 15 
countries (all in sub-Saharan Africa, except India) carried 80% of the global malaria 
burden (Fig. 1) [10]. 
The incidence rate of malaria is estimated to have decreased by 18% globally, from 76 to 
63 cases per 1000 population at risk, between 2010 and 2016. The South-East Asian 
region recorded the most significant decline (48%), followed by the Americas (22%) and 
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the African region (20%). Despite these reductions, between 2014 and 2016 substantial 
increases in case incidence occurred in the Americas, and marginally in the South-East 
Asian, Western Pacific, and African regions. 
 
Figure 1-World distribution and cases of death through malaria. 
 
Spots demonstrate the global distribution of P. falciparum and P. vivax infections correlating with the number of 
deaths caused by malaria in 2016 (indicated in blue) Data were available at http://www.who.int/en/. 
 
Plasmodium falciparum is the most prevalent malaria parasite in sub-Saharan Africa, 
accounting for 99% of estimated malaria cases in 2016. Outside of Africa, P. vivax is the 
predominant parasite in the Americas, representing 64% of malaria cases. Indeed, Brazil 
reported a 72% decline of local P. falciparum cases between 2010 and 2016. Furthermore, 
the transmission of the disease is focalized: nearly 45% of cases in Brazil come from 15 





Figure 2- Distribution of cases in Latin America. 
 
The map shows the confirmed malaria cases per 1000 population of 2016.  The population at risk is estimated to 
be 126.8 million. The confirmed cases decreased from 678.200 in 2010 to 562.800 in 2016 (17% decrease) and 
deaths decreased from 190 in 2010 to 110 in 2016 (42% decrease) [10]. 
 
1.1.2. Control and Resistance 
Two of the mechanical barriers used to control the vector are insecticide-treated mosquito 
nets (ITNs) and indoor residual spraying in areas of high risks. Between 2014 and 2016, 
manufacturers reported they had delivered 582 million ITNs globally. Of these, 505 
million ITNs were delivered in sub-Saharan Africa. Another type of net also in use is the 
long-lasting insecticidal net that contains pyrethroids, which protects for up to 3 years and 
is highly recommended, especially for young children and pregnant women, in endemic 
areas. However, mosquito resistance to pyrethroids is already reported and, in some areas, 
even all four classes of insecticides have already shown a decreased effect [10]. 
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There are several vaccines in development which inhibit the proliferation of the parasite at 
different points, from sporozoite to sexual stage development. The most prominent 
vaccine candidate for the prevention of P. falciparum is RTS,S/AS01. The RTS,S was 
implemented on a pilot scale, nonetheless, the major limitation of this candidate appears 
to maintain a high antibody titer [11]. 
One of the oldest known antimalarials is quinine, an alkaloid derived from the bark of the 
cinchona tree. It was brought in the 17
th
 century from Peru to Europe and it was first 
isolated in the 19
th
 century by French researchers Pierre Joseph Pelletier and Joseph 
Bienaimé Caventou. It remained the antimalarial drug of choice until the 1940s when 
chloroquine (CQ) took over [12]. Already in 1934, Hans Andersag had discovered the 
quinine-related antimalarial [13], which was used massively worldwide. All 4-
aminoquinolines—quinine, CQ, mefloquine, amodiaquine, and quinoline-methanols—are 
supposed to interfere with the plasmodial haem detoxification inside the digestive vacuole 
(DV), thereby killing the parasite [14, 15]. CQ had several advantages such as high 
efficacy, low production costs, and low toxicity; nonetheless after the selection of CQ-
resistant Plasmodium strains in the late 1950s it was necessary to find new drugs [3]. The 
resistance is mediated through mutations in the P. falciparum chloroquine resistance 
transporter (PfCRT) located on the DV membrane allowing the efflux of CQ [16, 17]. 
Antifolates were discovered as an alternative, acting through the inhibition of the 
biosynthesis of tetrahydrofolate (the active form of folate, vitamin B9), solely present in 
the parasite. Antibiotics like sulfadoxine (a sulfonamide antibiotic) inhibit the enzyme 
dihydropteroate synthetase, while pyrimethamine inhibites the dihydrofolate reductase 
and dihydropteroate synthase [18, 19]. To enhance their effect, both drugs were used in 
combination to inhibit two different steps in the same biosynthetic pathway. Nevertheless, 
in 1970 the selection of resistant strains was noted in Thailand; it spread rapidly through 
Asia and to the African continent. Indeed, selected strains resistant against all known 
antimalarials were spreading fast, which consequently required the development of new 
drugs. At this point artemisinin was discovered and isolated from a Chinese herb, 
Artemisia annua. Artemisinin was effective against all multi-drug resistant parasites [20]. 
Several artemisinin derivates exist that all reduce blood parasitaemia very rapidly. 
However, the drug´s half-life is very short, and for that reason the drug is given only in 
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combination with other antimalarials, and is known as artemisinin combination therapies 
(ATCs) [21]. These ACTs are part of the recent success in global malaria control, and 
protect their efficacy for the treatment of malaria, which is a global health priority. The 
main advantage of ACTs is that the artemisinin quickly kills most of the malaria parasites 
and the partner drug clears the remaining ones. However, the efficacy of ACTs is 
threatened by the emergence of both artemisinin and partner drug resistance. Today ATCs 
are the treatment of choice for uncomplicated malaria. Nevertheless, parasites with 
resistance to artemisinin have already been identified in 5 countries of South East Asia 
(Cambodia, Laos, Myanmar, Thailand, and Vietnam) [10]. 
 
Figure 3- Distribution of the resistant strains of P. vivax and P. falciparum 
 
In this interactive map, it is possible to select the drug and see the where the resistant strains are localized. The 
image above shows the strain P. falciparum resistance strain to dual treatment Dihydroartemisinin with 
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Piperaquine. The image below shows the distribution of P. vivax resistant strain to Chloroquine with Primaquine. 
The map is available in http://apps.who.int/malaria/maps/threats/[10].  
Another strategy of new antimalarials is to block the parasite transmission by targeting the 
liver or the sexual stages of the parasite. Till today there was just one drug family 
available attacking also hypnozoites. The 8-aminoquinolines like as primaquine is the 
only available drug to use for relapsing malaria caused by P. vivax or P. ovale. The 
mechanism of action is still unclear but probably involves cytochrome P450s and 
monoamine oxidase, as well as the formation of reactive intermediates [22]. However, this 
drug is not recommended for glucose-6-phosphate-deficient patients as well as for 
pregnant woman since the drug could produce haemolytic anaemia. 
For P. vivax, chloroquine remains an effective first-line treatment in many countries. 
Actually, the first-line treatment policy is Artemether-lumefantrine (AL) in Bolivia, 
Brazil, Colombia, Ecuador, French Guiana, Guyana, Panama and Suriname; artesunate-
mefloquine (AS MQ) in Brazil, Peru and Venezuela; and chloroquine together with 
primaquine in Costa Rica, Dominican Republic, Guatemala, Haiti, Honduras and 
Nicaragua. Apart from one small study conducted in Suriname in 2011 (which detected a 
9% treatment failure rate of AL), studies in the period 2010–2016 showed effective first-
line treatment for P. falciparum. Artemisinin resistance was suspected in French Guiana, 
Guyana and Suriname, but molecular markers of artemisinin resistance (PfK13 C580Y) 
were only detected in a retrospective study of Guyanese samples from 2010, and a more 
extensive survey in 2016 confirmed the emergence of artemisinin resistance with a genetic 
profile compatible with a South American origin [10].  
The inevitable emergence of antimalarial drug resistance [23, 24]  forces continuous 
efforts toward the discovery and development of new antimalarial drugs [25–30]. 
Recently, the Food and Drug Administration has approved the drug Krintafel 
(tafenoquine) as a single dose medication for the treatment of hypnozoites caused by 
Plasmodium vivax. Nonetheless, the need is urgent for novel chemotherapeutic targets. 
New drugs should be created [31–35] to target solely the parasite with minimal (or no) 
toxicity to the human host. Therefore, good drug targets should be sufficiently different 




1.2. Comprehensive life cycle of Plasmodium  
All Plasmodium spp. share a complex life cycle within the insect and the vertebrate host. 
Human malaria is transmitted via the female Anopheles mosquito, which injects 
sporozoites during a blood meal. After invading liver cells, each sporozoite can mature 
into up to 40,000 merozoites, which will then be released into the bloodstream via 
merosomes [36]. However, P. vivax and P. ovale are able to form hypnozoites, an 
attenuated form of liver schizont, which can remain in the liver for several months before 
proceeding to the blood stage. The released merozoites can infect red blood cells (RBCs), 
causing these cells to remodel in order to facilitate their proliferation and differentiation 
from ring to trophozoite and then into schizont. 
 
Figure 4- Comprehensive lifecycle of Plasmodium falciparum 
 
The life cycle of Plasmodium spp. is occurring in two hosts. After a blood meal of the female of Anopheles 
mosquito, the parasite infects human hepatocytes and proliferates into merozoites. While an infection with P. 
vivax or P. ovale can lead to a sporozoite differentiation into hypnozoites in all other cases merozoites will 
directly infect RBC and replicate via schizogony. This asexual replication can be repeated infinitely. Other 
merozoites develop into male and female gametocytes that infect mosquitoes when taken up by the next blood 
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meal. The sexual stages mature into the mosquito gut where they fuse and form an ookinete. The ookinete 
develops into the oocyst which releases new sporozoites that migrate to the insect's salivary glands (Modified 
from [37]). 
 
One of the reasons for the high virulence of P. falciparum is the export of PfEMP1 
(Plasmodium falciparum infected erythrocyte membrane protein 1) to the infected RBC 
(iRBC) surface. PfEMP1 allows the iRBC to bind to the endothelium, avoiding its 
clearance by the spleen and leading to a disrupted blood flow which can cause cerebral or 
placental malaria when they occur in the brain or placenta [38]. The asexual blood cycle is 
responsible for anemia and periodic fevers characteristic of the disease as it ends with the 
haemolysis and release of new merozoite forms into the bloodstream. While most of the 
merozoites will reinfect other erythrocytes, some differentiate into male and female 
gametocytes. These gametocytes differentiate into gametes within the mid-gut of a female 
Anopheles mosquito after the next blood meal, and sexual proliferation takes place. After 
the diploid zygote forms, the zygote differentiates to the ookinete and later oocyst, and 
subsequently new sporozoites are formed. The released sporozoites migrate to the 
mosquito’s salivary gland, where they will be transmitted during its next blood meal [37]. 
1.3. Pyrimidines Biosynthesis  
Our group has focused on the need for certain nutrient requirements for the the malaria 
parasite to proliferate [39–42], such as vitamins, sugars, and amino acid metabolites [43–
45]. In the latter nutrient, we focused on aspartate metabolism. This metabolite is not only 
important for the maintenance of the unique tri-carbon-acid cycle in P. falciparum [39, 
46]–[48] as well as a constituent within the protein biosynthesis, but it is also involved in 
a variety of metabolic reactions [49–52] such as the initiation of pyrimidine biosynthesis, 
which has fundamental importance in the survival of the malaria parasite [44], [53], [54].  
Furthermore, in Plasmodium species, besides the DNA, the pyrimidine nucleotide is also 
involved in the biosynthesis of RNA, phospholipids, and glycoproteins [55–57]. 
Plasmodium parasites rely on the de novo pyrimidine–biosynthesis pathway for their 
proliferation (Fig. 5). All the genes encoding for the enzymes of the de novo synthesis, as 
well as the uracil pyrimidine salvage enzymes, were found in the genome database of the 
parasite. The enzyme activities include inter-converting uracil, uridine, and UMP of the 
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pyrimidine salvage pathway (uracil phosphoribosyltransferase, UPRT; uridine 
phosphorylase, UP; uridine kinase, UK) were demonstrated in P. falciparum [58]. Despite 
the presence of the salvage pathway, the parasites depend exclusively on the de novo 
pathway as a source of pyrimidines for their survival, which may relate to the fact that 
mature mammalian erythrocytes lose their ability to synthesize pyrimidines. [56], [59], 
[60]. 
 
Figure 5- Biosynthesis of Pyrimidines. 
 
Pyrimidine biosynthesis in Plasmodium falciparum. In purple, there are the enzymes present in the parasite and 




The first enzyme of the pathway is the carbamoyl phosphate synthetase II (CPSII) that is 
responsible for the formation of carbamoyl phosphate from bicarbonate, glutamine, and 
ATP [61]. This enzyme with the molecular mass of 275kDa is one of the biggest genes in  
the genome of P. falciparum. Flores et al. show that this enzyme is a control point, being 
inhibited by UTP and activated by α-D-phosphoribosyl pyrophosphate (PRPP) [61]. 
The second enzyme, aspartate transcarbamoylase (PF3D7_1344800, ATCase) catalyzes 
the condensation of aspartate and carbamoyl phosphate to form N-carbamoyl-l-aspartate 
and inorganic phosphate.  
 
Figure 6 - Reaction of Aspartate Carbamoyltransferase 
 
The substrates of the reaction are carbamoyl phosphate and aspartate, the ATCase catalyse the transference of 
carbamoyl group to the aspartate, releasing inorganic phosphate and carbamoyl aspartate.  
 
From this step, the pathway follows basically the same steps found in the human host and 
in other eukaryotes: orotate is formed by dihydroorotase (DHOase) and dihydroorotate 
dehydrogenase (DHODH). The enzyme orotate phosphoribosyl transferase (OPRTase) 
catalyzes the formation of orotidine 5′-monophosphate (OMP) from PRPP and orotate, the 
fifth step within the pyrimidine biosynthesis. The metabolite PRPP is synthesized by an 
enzyme from outside of the pathway, namely phosphoribosylpyrophosphate synthetase 
(PRSase), which will be described later. Orotidine 5′-monophosphate decarboxylase 
(OMPDCase) catalyzes the final step of the pathway: the decarboxylation of orotidine 5′-
monophosphate (OMP) to uridine 5′-monophosphate (UMP), which is the precursor of all 
other pyrimidine nucleotides and deoxynucleotides needed for nucleic acid synthesis [62]. 
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These last two steps of the pyrimidine biosynthesis in P. falciparum are catalyzed by a 
heteromeric complex that consists of two homodimers of PfOPRTase and PfOMPDCase 
encoded by two separate genes [63, 64]. 
In prokaryotes and plants, the first three enzymes of the pathway–CPSase, ATCase, and 
DHOase–are encoded as separate proteins that either act independently or are associated 
into complexes. In contrast, in animals the CPSase, ATCase, and DHOase activities are 
assembled as different domains within a single multifunctional polypeptide of 
approximately 240 kDa named CAD (an acronym for the three catalytic activities), in 
which the ATCase occupies the most C-terminal position [65]. As well as CAD, in 
humans OPRTase and OMP decarboxylase are fused together in one gene. In fungi, 
CPSase and ATCase are fused into a CAD-like polypeptide that contains a catalytically 
inactive DHOase-like domain, and this activity is provided by a separate protein. 
In Plasmodium, the ORFs of the first six enzymes – PfCPSII (chromosome 13), 
PfATCase (chromosome 13), PfDHOase (chromosome 14), PfDHOD (chromosomes 7 & 
9), PfOPRTase (chromosomes 5&7), PfOMPDCase (chromosome 10), including PfCA 
(chromosome 11) and PfUP (chromosomes 5&7) – were identified and located on various 
chromosomes. Krungkrai et al. show that the malarial CPS, DHOase, and OPRTase genes 
were conserved to bacterial counterparts, whereas ATCase, DHODH, and OMPDCase 
were mosaic variations that were homologous to both bacterial and eukaryotic 
counterparts, including human [58].  
1.3.1. Aspartate transcarbamoylase (ATCase) 
Since the 50s the aspartate transcarbamoylase (EC 2.1.3.2) from Escherichia coli has been 
studied intensively, being a paradigm of feedback inhibition and a model of cooperativity 
and allosteric regulation. Today, it is present in most textbooks on kinetics [49, 66, 67]. In 
prokaryotes, ATCases are organized into three major groups (Fig. 7) depending on 
whether the catalytic trimers function independently (e.g., Bacillus subtilis) or are 
associated face to face through DHOase (Aquifex aeolicus) or regulatory dimers 
(Escherichia coli) [68]. This last one was fully characterized by William Lipscomb and 
colleagues. EcATCase is known to be a highly regulated enzyme: it controls the rate of 
pyrimidine biosynthesis in response to cellular levels of both purines and pyrimidines 
[69]. As an allosteric enzyme, ATP and CTP, end products of purine and pyrimidine 
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pathways respectively, stimulate and inhibit the ATC catalytic activity. These two 
allosteric effectors can bind to the regulatory subunits, producing conformational changes 
in the structure, which relies on the regulation of the entire pathway [70, 71]. Indeed, the 
dissociation of the ecATCase holoenzyme results in isolated catalytic trimers that, similar 
to B. subtilis ATCase (Fig. 7), lack cooperativity and allosteric regulation. 
 
Figure 7- Different quaternary organizations of prokaryotic ATCases. 
 
Scheme of quaternary structures of different ATCases. In B. subtilis the native structure of the protein is a 
homotrimer, in E. coli there is two trimers attach with three dimers of regulatory subunits and finally, in A. 
aeolicus the two trimers are also anchored with three dimers of DHOase. Modified from [72]. 
 
The interesting characteristic among these enzymes is that the active site is formed in the 
interphase of two subunits, both polypeptide chains contribute to the cavity of the active 
site. Noteworthy is that the basic catalytic conformation of this enzyme is three subunits 
that could lead to the formation of a trimer or a hexamer; this pattern is repeated in most 




Figure 8- Three dimensional structure of Escherichia coli ATCase 
 
Quaternary structure of ATCase from E. coli in the T (left) and R (right) states with the molecular 3-fold axis 
vertical (top) and viewed down the molecular 3-fold axis (bottom). The molecule expands 11 Å along the 3-fold 
axis during the allosteric transition. The catalytic chains are shown in shades of blue and the regulatory chains 
are shown in yellow and nude. Modified from [74]. 
Regarding the kinetics, the mechanism of the enzyme was reported to be an ordered-
binding, where carbamoyl phosphate (CP) must bind before aspartate (Asp) and 
carbamoyl aspartate (CA) departing before inorganic phosphate (Pi) [49]. 
Structural studies by stop flow techniques, made from B. subtillis ATCase, revealed an 
extensive conformational change induced by CP binding, reducing the volume of the 
active site cavity by one-half. This binding is responsible for the creation of active sites 
that have high-activity and high-affinity for aspartate. Thus, CP binding is responsible for 
the induction of a positive cooperativity effect. The binding of CP not only creates a 
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physical pocket to bind Asp but also changes considerably the electrostatic environment 
of the active site. The binding of aspartate induces a closure in the domains that assists in 
lowering the activation energy, producing catalysis [75].  
In contrast, in the ATCase holoenzyme of E. coli, the aspartate produces this 
conformational movement that causes the necessary loop movements inducing 
cooperativity [75]. This phenomenon is explained by an Asp-induced conversion of the 
holoenzyme from a “T” (tense) state, where active sites are constrained in an open 
conformation with low activity and low affinity for Asp, to a relaxed “R” state with 
increased affinity and activity. 
A common characteristic in the kinetics of many ATCases is the strong substrate 
inhibition by aspartate [76]; it appears that aspartate has the ability to bind to the same site 
as CP in the non-liganded form.  
1.3.1.1. Inhibitors of Aspartate transcarbamoylase 
In the literature, N-phosphonacetyl-L-aspartate (PALA) is a well-known inhibitor among 
the ATCases. A potent inhibitor, PALA combines the features of the two substrates and 
resembles the transition state of the reaction (Fig. 9). Inhibition is competitive in CP and 
non-competitive in aspartate, proving again the ordered binding mechanism, with CP 
binding to the enzyme prior to aspartate for catalysis to occur. Moreover, the molecule 
was also used to perform co-crystallization experiments with ATCases of several 





Figure 9- Three dimensional structure of substrates of ATCase and PALA. 
 
Structure of two substrates of ATCases, L-Aspartate and Carbamoyl Phosphate, as well as N-phosphonacetyl-L-
aspartate (PALA), a well known inhibitor of the protein. In this image, it is easy to see the similarities between 
the structures. 
 
In the 1970s several studies demonstrated that PALA is able to inhibit CAD, the human 
complex [13] and stop the proliferation of cancer cells in culture [78]. Indeed, PALA 
demonstrated a broad spectrum of activity against experimental tumor models, and its 
biochemical and pharmacological effects are well characterized. Phase I trials were 
followed by broad Phase II screening for antitumor activity. Unfortunately, PALA was 
inactive as a single agent [79].  
 
1.3.2. Phosphoribosylpyrophosphate synthetase (PRSase) 
Phosphoribosylpyrophosphate synthetase (EC 2.7.6.1) is an enzyme that catalyzes ribose 
5-phosphate into phosphoribosyl pyrophosphate (PRPP), using ATP as a donor of 
pyrophosphate and releasing AMP (Fig. 10). The product of the reaction, PRPP, is a key 
metabolite of several important pathways, such as synthesis of nucleotides (Fig. 5), 




Figure 10 - Schematic illustration of catalysis of the phosphoribosylpyrophosphate 
synthetase (PRSase) 
 
The enzyme catalyzed the transference of pyrophosphate from ATP to the carbon number 1 of the ribose-5 
phosphate, forming the Phosphoribosyl pyrophosphate, which plays a role in transferring phospho-ribose groups 
in several reactions. 
 
This enzyme came to be known after the publications of Sun et al. and Hanson et al. 
These authors reported a potent antimalarial drug called Torin2, which has an EC50 for 
asexual blood stages to be 1.4 nM, as well as being highly potent against early 
gametocytes, with a slightly lower EC50 of 6.62 nM. Additionally, they reported that 
Torin2 attached to a specific matrix and could bind 3 proteins after passing a lysate of 
gametocytes of P. falciparum. These 3 proteins were aspartate carbamoyltransferase 
(PF3D7_1344800, ATCase), phosphoribosylpyrophosphate synthetase (PF3D7_1325100, 
PRSase), and a putative transporter (PF3D7_0914700). As our work is focusing on 
aspartate carbamoyltransferase and to continue with our research line, we decided to set 
up the characterization and preliminary crystallization experiments of plasmodial 
Phosphoribosylpyrophosphate synthetase (PfPRSase) [80, 81]. 
 
  
